- Home
- TMCI vs CELC Comparison
TMCI vs CELC Comparison
Compare TMCI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMCI
- CELC
- Stock Information
- Founded
- TMCI 2014
- CELC 2011
- Country
- TMCI United States
- CELC United States
- Employees
- TMCI N/A
- CELC N/A
- Industry
- TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CELC Medical Specialities
- Sector
- TMCI Health Care
- CELC Health Care
- Exchange
- TMCI Nasdaq
- CELC Nasdaq
- Market Cap
- TMCI 449.2M
- CELC 440.0M
- IPO Year
- TMCI 2021
- CELC 2017
- Fundamental
- Price
- TMCI $7.07
- CELC $53.07
- Analyst Decision
- TMCI Hold
- CELC Strong Buy
- Analyst Count
- TMCI 5
- CELC 5
- Target Price
- TMCI $8.60
- CELC $53.60
- AVG Volume (30 Days)
- TMCI 320.3K
- CELC 886.2K
- Earning Date
- TMCI 11-04-2025
- CELC 11-13-2025
- Dividend Yield
- TMCI N/A
- CELC N/A
- EPS Growth
- TMCI N/A
- CELC N/A
- EPS
- TMCI N/A
- CELC N/A
- Revenue
- TMCI $213,751,000.00
- CELC N/A
- Revenue This Year
- TMCI $10.63
- CELC N/A
- Revenue Next Year
- TMCI $9.43
- CELC N/A
- P/E Ratio
- TMCI N/A
- CELC N/A
- Revenue Growth
- TMCI 7.67
- CELC N/A
- 52 Week Low
- TMCI $4.54
- CELC $7.58
- 52 Week High
- TMCI $10.79
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- TMCI 51.69
- CELC 52.59
- Support Level
- TMCI $6.93
- CELC N/A
- Resistance Level
- TMCI $7.50
- CELC $63.06
- Average True Range (ATR)
- TMCI 0.32
- CELC 3.04
- MACD
- TMCI -0.07
- CELC -3.14
- Stochastic Oscillator
- TMCI 20.00
- CELC 84.16
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.